World Health Organization

Department of Immunization, Vaccines and Biologicals (IVB)

SAGE

meeting

SLIDE DECKS

Strategic Advisory Group of Experts on Immunization
3-6 October 2022

Hybrid meeting, WHO
Geneva, Switzerland

Note: To work properly this pdf needs to be downloaded on your computer (PC/Mac) and opened in Acrobat reader. It is does not function correctly in an internet browser window or on handheld devices.

World Health Organization

1- Download Pdf
2- Open file in Acrobat Reader
3- Click on the icons to access presentations

Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
3–6 October 2022
Hybrid Meeting.
WHO HQ. Salle V

Day 1: Monday, 3 October 2022 (time is Central European Time)

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	**Closed SAGE meeting**	Preparation of the sessions of the day.	**1h**
10:30	**Break**	**Break**	**15 min.**
10:45	**Opening and welcome – introduction of participants** K. O'BRIEN, IVB Director WHO. A. CRAVIOTO, SAGE chair J. HOMBACH, SAGE secretariat WHO.	**Opening of the Plenary Meeting by DG WHO (tbc)**	**15 min.**
11:00	**Global Reports – Session 1** Report from the Director of IVB. K. O'BRIEN, WHO. 30 min. Update from Gavi. S. BERKLEY, GAVI. 10 min. Discussion. 20 min	**FOR INFORMATION**	**1h.**
12:00	**IA2030 and Regional updates – Session 2** Brief introduction of the session and objectives. F. OLAYINKA and N. MACDONALD, SAGE members. 5 min Overview of IA2030 implementation progress. A.M. ROPERO. WHO. 15 min Overview of IA2030 Technical Progress Report analyses. J. GREVENDONK. WHO. 20 min. Discussion. 10 min	**FOR RECOMMENDATION** Brief update on IA2030 implementation progress, in line with the IA2030 Framework for Action. Present the IA2030 Technical Progress Report for 2022, including analyses of global and regional progress towards IA2030 impact goal targets and strategic priority objectives.	**50 min (3h20 in total)**
12:50	**Break**	**Break**	**45 min.**
13:35	**IA2030 and Regional updates – Session 2 (continued)** Reports from the Regions. WHO. 1h30 AFRO. J. MATHIU and EMRO. Q. HASAN. 10 min each + 10 min Q&A EURO. S. DATTA and PAHO. D. SALAS. 10 min each + 10 min Q&A WPRO. Y. TAKASHIMA and SEARO. S. BAHL. 10 min each + 10 min Q&A Overview of IA2030 Partnership Working Group recommendations for consideration by SAGE. E. MAST. IA2030 M&E WG chair. 20 min. Discussion. 40 min.	**FOR RECOMMENDATION** Present considerations for technical and policy-related recommendations to address corrective actions needed to address widening immunization gaps. Receive decisions from SAGE on these proposed recommendations developed collectively across the IA2030 partnership.	**2h30 (3h20 in total)**
16:05	**End of day**		

Day 2: Tuesday 4 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	**Closed SAGE meeting**	Development of recommendations of day 1. Preparation of the sessions of the day. Other important discussion items.	**1h30**
11:00	**Break**	**Break**	**15 min.**
11:15	**Orthopox/Monkeypox – Session 3** Introduction of session, K. NEUZIL. SAGE member and Working Group chair. 5 min. Update on Monkeypox epidemiology. R. LEWIS. WHO. 10 min.  WHO global strategy on monkeypox vaccination. T. CERNUSCHI, WHO. Q&A. 15 min. Evidence on vaccine safety, immunogenicity, efficacy and safety of the vaccines currently used in the outbreak response. J. VAN HOLTEN. WHO. Q&A. 20 min. Draft recommendations. K. NEUZIL. SAGE member and Working Group Chair. 20 min. Q&A and discussion. 50 min.	**FOR RECOMMENDATION** Provide a brief update on Monkeypox epidemiology and ongoing vaccine interventions, including vaccine access/supply Present and discuss WHO's strategy on Monkeypox vaccination in context of the Public Health emergency of international concern (PHEIC) Recommend any update needed to WHO's interim guidance on Monkeypox vaccination based on rapid evidence reviews and early experience from vaccination, with specific consideration of: – Post exposure vaccination – Pre-exposure vaccination target groups – Vaccination strategies for special populations – Vaccine choices	**2h**
13:15	**Break**	**Break**	**1h.**
14:15	**RSV – Session 4** Introduction of session. K. NEUZIL. SAGE member. 5 min. New RSV global burden of disease estimates, results from community mortality studies and RSV surveillance under GISRS. D. FEIKIN. WHO. 15 min.  Pipeline of late stage candidates and timelines for mAbs and maternal vaccines. Clinical trial results for nirsevimab phase 3 and phase 2b Pfizer maternal vaccine. E. SPARROW. WHO. 15 min. Summary of TAG discussion on additional data needs from LMICs. H. ZAR. RSV TAG chair. 25 min. Discussion. 30 min.	**FOR DISCUSSION** SAGE input on what additional information (if any) would be needed for a policy recommendation for the two lead candidates, nirsevimab and the Pfizer maternal vaccine data needs for policy (vaccines)	**1h30**
15:45	**End of the day**		

Day 3: Wednesday 5 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	**Closed SAGE meeting**	Development of recommendations of day 2. Preparation of the sessions of the day. Other important discussion items.	**1h30**
11:00	**Break**	**Break**	**15 min.**
11:15	**Polio – Session 5** Session overview. I. JANI. SAGE member. 5 min. Update from the Global Polio Eradication Initiative. A. O'LEARY. WHO. 20 min. Questions and answers. 20 min.  IPV as an option for VDPV outbreak response in IPV-only using countries. O. MACH. WHO. 15 min. Questions and answers. 5 min. Role of older children in poliovirus transmission. O. MACH. WHO. 10 minutes. Questions and answers. 5 min. Report from SAGE Polio Working Group including update on novel OPVs. I. JANI, SAGE Member. 15 min. Discussion. 10 min.	**FOR RECOMMENDATION** SAGE will be informed on the current status of the polio eradication programme and of the implementation of the new polio eradication strategy. SAGE will be updated on the use and clinical development of novel OPVs. SAGE will be asked to review and consider for endorsement: • WG's recommendation on "Options for VDPV outbreak response in IPV-only using countries" • WG's recommendation on criteria for expanding age group in poliovirus outbreak response vaccination campaigns	**1h45**
13:00	**Break**	**Break**	**45 min.**
13:45	**COVID-19 vaccines – Session 6** ***Variant-containing vaccines*** Waning protection against new variants both from vaccine and infection-induced immunity. M. PATEL. WHO. 20 min.  Immunogenicity data from variant-containing vaccines. M. CAVALERI. EMA. 20 min. Discussion. 30 min. Policy recommendation. A. WILDER-SMITH. WHO. 20 min. ***Corbevax (Biological E) Covid-19 vaccine review*** Evidence review. Presentation by the company. 30 min. Evidence to recommendation tables: T. SHARMA. WHO. 15 min. Policy recommendations. H. NOHYNEK. SAGE member and SAGE COVID-19 WG chair. 15 min. Discussion. 30 min.	**FOR RECOMMENDATION** To formulate policy recommendations for the use of variant-containing vaccines To formulate policy recommendations for use of Corbevax COVID-19 vaccine, once EUL is obtained	**3h**
16:45	**End of the day**		

Day 4: Thursday 6 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	**Closed SAGE meeting**	Development of recommendations of day 3. Preparation of the sessions of the day. Other important discussion items.	**1h30**
11:00	**Break**	**Break**	**15 min.**
11:15	**Ebola – Session 7** Introduction. A. M. HENAO-RESTREPO. WHO. 5 min. Epidemiological situation of the Sudan ebolavirus outbreak in Uganda. C. NJUGUNA. WHO. 10 min. Phylogeny of ebolaviruses. C. MUÑOZ-FONTELA. Bernhard Nocht Institute for Tropical Medicine, Germany. 10 min. Evidence regarding current Zaire ebolavirus vaccines and potential for crossprotection against Sudan ebolavirus. W. DOWLING, CEPI. 10 min. Candidate vaccines against Sudan ebolavirus. S. FUNNELL, Quadram Institute Norwich, UK. 10 min. Proposed randomized ring vaccination trial to assess vaccine efficacy. R. PETO. University of Oxford, UK. 10 min. Other priority research agenda items and next steps. A. M. HENAO-RESTREPO. WHO. 10 min. Discussion. 55 min.	**BRIEFING FOR INFORMATION** *Change of programme due to the recent Sudan ebolavirus outbreak in Uganda* (The previously schedule recommendation session on developing policy recommendations for Ebola-Zaire vaccination will be postponed to an extraordinary SAGE meeting)	**2h**
13:15	**End of SAGE Plenary meeting**		
13:15	**Break**	**Break**	**1h**
14:15	**Closed SAGE session**	Meeting wrap up.	**2h**
16:15	**End of final closed meeting**		